FGF4

(redirected from FGF-4)

FGF4

A gene on chromosome 11q13.3 that encodes fibroblast growth factor 4 of the FGF family, which bind heparin and have a broad range of cellular activities, including cell survival, division, differentiation and migration, embryonic development, morphogenesis, tissue repair, tumour growth and invasion. FGF4 is required for normal limb and cardiac valve development during embryogenesis. It interacts with FGF receptors FGFR1, -2, -3 and -4.
References in periodicals archive ?
The transfected heart cells then express and release FGF-4 protein, which promotes the growth of new blood vessels that increase blood flow to ischemic heart tissue.
The substance of AGT-MI, Ad5FGF-4, is an adenoviral vector that has been designed to transport the gene that encodes for the growth factor FGF-4 into cells of the heart, leading to the formation of new small blood vessels (angiogenesis).
A dual recombinant which combined an FGF-4 gene and a VEGF-145 gene has been shown to be associated with a favorable treatment effect in an animal model of coronary artery disease.
This collaboration has now been broadened to include the study of additional forms of FGF-4 and their interaction with biological receptors.
In fact, a dual recombinant that combined a VEGF-145 gene and an FGF-4 gene was recently shown to be associated with a favorable treatment effect in an animal model of coronary artery disease.
In collaboration with researchers at Essen BioScience (Ann Arbor, MI), Cardium has developed an angiogenic bioassay for commercial batch release, which in addition to Cardium's already established potency assay, directly demonstrates the ability of FGF-4 protein expressed by Generx to promote new blood vessel formation.
Researchers believe that central to the biological activity and potential therapeutic benefit of Generx is the effective capture of the Ad5 delivery vector in the coronary micro-circulation, subsequent vector uptake, and FGF-4 protein expression (preferentially in myocytes and endothelial cells).
In March 2000, the Company reported positive results from a double-blind, placebo-controlled Phase 1/2 clinical trial of its lead product candidate, GENERX(TM), a non-surgical angiogenic gene therapy for the treatment of angina due to coronary artery disease, that utilizes the FGF-4 gene licensed from NYU.
This unique dual recombinant angiogenic growth factor gene was constructed using a form of the FGF-4 gene, exclusively licensed by Collateral from New York University, in combination with a form of the VEGF-145 gene, exclusively licensed from Dimotech Ltd.
These laboratory results are similar to those produced by other genes, such as VEGF-1, FGF-1 and FGF-4, which have been shown in human clinical studies to regenerate new blood vessels in heart muscle and in the limbs.
Collateral's lead proprietary non-surgical angiogenic product, GENERX(TM), is based upon the FGF-4 gene.